Cardiff Oncology Prices $10M Registered Direct Offering at Premium to Market, Extends Cash Runway Amid Going Concern
CRDF is trading near its 52-week low of $0.83 (6.0% above the low) on elevated volume (9.1× avg).
Summary
Cardiff Oncology raised $10.05 million in a registered direct offering at a premium to its current stock price, with insider participation, extending its cash runway amid a going concern warning and a critical license dispute for its lead drug.
Key Events · Financing and Capital Events · CRDF
-
$10.05M Registered Direct Offering
In a registered direct offering, Cardiff Oncology sold 9,293,078 shares with accompanying warrants, raising $10.05 million in gross proceeds before fees. Institutional investors paid $1.05 per unit, while insiders paid $1.455 per unit.
-
Priced at Premium to Market
The institutional unit price of $1.05 represents a 19% premium to today's $0.8801 stock price, signaling institutional demand even in the company's distressed situation.
-
Insider Participation at Higher Price
Demonstrating management's commitment, officers and directors purchased 721,649 units at $1.455 per unit—a 65% premium to the current stock price.
-
Warrants Add Potential Future Dilution
Investors received Common Warrants to purchase 9,293,078 shares at $1.31 per share. Exercisable after six months and contingent on an authorized share increase, these warrants could potentially double the share count if exercised.
Analysis · CRDF · Life Sciences
Amid a going concern warning and a critical license dispute, Cardiff Oncology secured $10.05 million through a registered direct offering that signals institutional confidence—units were priced at $1.05 for institutions, a premium to today's $0.88 stock price. Insider participation at $1.455 per unit further underscores management's alignment. The $9.1 million in net proceeds stretches the cash runway beyond the previously projected Q1 2027, buying time to advance onvansertib's Phase 3 program and resolve the Nerviano litigation. Yet the transaction is highly dilutive: 9.3 million new shares increase the outstanding count by 13.6%, with additional potential dilution from warrants exercisable at $1.31. That the company needed to raise capital at this stage, despite positive Phase 2 data, highlights the financial strain imposed by the license termination threat.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1156 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDF was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.8M. The 52-week trading range was $0.83 to $4.56. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.